Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Andreas Hettich GmbH & Co. KG has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is handled by 1 distinct examiner and is located in 1 distinct art unit. ISMAIL, REHANA is the busiest examiner for the company, responsible for 1 pending office action. The current workload for Andreas Hettich GmbH & Co. KG consists of this single pending matter, reflecting a highly specific prosecution stage.
The assignment of the 1 pending office action to a single individual means that ISMAIL, REHANA directs the current prosecution strategy. This 1 distinct art unit serves as the sole venue for the company's active patent office engagement. For practitioners, this indicates that all current interactions are centralized within one technical unit and under one examiner. This 1 to 1 ratio of actions to examiners ensures a singular focus for the company's active biotechnology matters.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ISMAIL, REHANA | 1 | 76.2% | +34.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17996370 | PHOSPHOLIPIDS AND PHOSPHOLIPID METABOLITES FOR TREATING VIRAL AND BACTERIAL PNEUMONIA AND SEPSIS | ISMAIL, REHANA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17996370 | PHOSPHOLIPIDS AND PHOSPHOLIPID METABOLITES FOR TREATING VIRAL AND BACTERIAL PNEUMONIA AND SEPSIS | ISMAIL, REHANA | — |
| Art Unit | Apps |
|---|---|
| 1625 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17996370 | PHOSPHOLIPIDS AND PHOSPHOLIPID METABOLITES FOR TREATING VIRAL AND BACTERIAL PNEUMONIA AND SEPSIS | ISMAIL, REHANA | 1625 | §103§112 | Non-Final OA | — | Pending | Jun 13, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAndreas Hettich GmbH & Co. KG has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Rehana Ismail has the most, with 1 of Andreas Hettich GmbH & Co. KG's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
